Spectral MD Holdings, Ltd. Exercise of Options (4539K)
25 Agosto 2023 - 1:00AM
UK Regulatory
TIDMSMD
RNS Number : 4539K
Spectral MD Holdings, Ltd.
25 August 2023
Spectral MD Holdings, Ltd
("Spectral MD" or the "Company")
Exercise of Options
LONDON, U.K. AND DALLAS, TX, U.S. -Spectral MD Holdings, Ltd.
(AIM: SMD), an artificial intelligence (AI) company focused on
medical diagnostics for faster and more accurate treatment
decisions in wound care, announces the exercise of options (the
"Exercise") by certain employees of the Company including the
Company's CEO, Wensheng Fan (together the "Employees") as detailed
below.
The Employees have exercised options over an aggregate of
1,155,159 shares of common stock of US$0.001 each in the Company
("Common Stock").
796,587 shares of Common Stock have been issued and allotted
pursuant to the Company's 2018 Long-Term Incentive Plan. As
previously announced on 7 November 2022, up to 2 million shares of
Common Stock under the 2018 Long-Term Incentive Plan were
previously admitted to trading on AIM pursuant to a block listing
application. A further 358,572 shares of Common Stock have been
issued and allotted pursuant to the Company's Investor Options, as
detailed below.
Director/PDMR Shareholding
Pursuant to the Exercise, Wensheng Fan, Chief Executive Officer,
has exercised options over 358,572 shares of Common Stock at an
exercise price of US$0.20 per share of Common Stock.
As a result, Wensheng Fan's beneficial interest in the Company
is 1,858,572 shares of Common Stock, representing approximately
1.35% of the total issued share capital.
Admission and Total Voting Rights
The Company will apply for 358,572 shares of Common Stock to be
admitted to trading on AIM, with admission expected to take place
at 8:00 a.m. on or around 31 August 2023 ("Admission"). The shares
of Common Stock will rank pari passu in all respects with existing
Common Stock. A further 796,587 shares of Common Stock were
previously admitted to trading pursuant to a block listing.
Following Admission, there will be 137,404,723 ordinary shares
of Common Stock of US $0.001 each in issue, with one voting right
per share of Common Stock. The total number of voting rights in the
Company will therefore be 137,404,723.
This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
issued share capital of the Company under the Company's Certificate
of Incorporation. No Common Stock is held in treasury.
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 as it forms part of
UK domestic law by virtue of the European Union (Withdrawal) Act
2018 ("MAR"). Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is
now considered to be in the public domain.
For further information please contact:
Spectral MD Holdings, Ltd. IR@Spectralmd.com
Wensheng Fan, Chief Executive Officer via Walbrook PR
Nils Windler, Chief Financial Officer
SP Angel Corporate Finance LLP (NOMAD and Joint Broker for Spectral MD) Tel: +44 (0)20 3470 0470
Stuart Gledhill / Harry Davies-Ball (Corporate Finance)
Vadim Alexandre / Rob Rees (Sales & Broking)
The Equity Group Inc. (US Investor Relations) dsullivan@equityny.com
Devin Sullivan Tel: 212-836-9608
Walbrook PR Ltd (UK Media & Investor Relations) spectralMD@walbrookpr.com
Paul McManus / Louis Ashe-Jepson / Alice Woodings Tel: +44 (0)20 7933 8780
About Spectral MD
Spectral MD is a predictive AI company focused on medical
diagnostics for faster and more accurate treatment decisions in
wound care for burn, DFU, and future clinical applications. At
Spectral MD, we are a dedicated team of forward-thinkers striving
to revolutionize the management of wound care by "Seeing the
Unknown"(R) with our DeepView(R) Wound Diagnostics System. The
Company's DeepView(R) platform is the only predictive diagnostic
device that offers clinicians an objective and immediate assessment
of a wound's healing potential prior to treatment or other medical
intervention. With algorithm-driven results that substantially
exceed the current standard of care, Spectral MD's diagnostic
platform is expected to provide faster and more accurate treatment
insight, significantly improving patient care and clinical
outcomes. For more information, visit the Company at:
www.spectralmd.com.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Wensheng Fan
----------------------------- ------------------------------------
2. Reason for the Notification
-------------------------------------------------------------------
a) Position/status CEO
----------------------------- ------------------------------------
b) Initial Initial notification
notification/Amendment
----------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Spectral MD Holdings, Ltd
----------------------------- ------------------------------------
b) LEI 213800VXW1FVGWTCKL44
----------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Common Stock of US$0.001 each
of the Financial
instrument,
type of
instrument
Identification USU8457V1099
code
----------------------------- ------------------------------------
b) Nature of Exercise of Options
the transaction
----------------------------- ------------------------------------
c) Price(s) Price(s) Volume(s)
and volume(s) 1. US$0.20 358,572
----------
----------------------------- ------------------------------------
d) Aggregated Price(s) Volume(s)
information: US$0.20 358,572
- Aggregated ----------
volume
- Price
----------------------------- ------------------------------------
e) Date of 18 August 2023
the transaction
----------------------------- ------------------------------------
f) Place of Outside a trading venue
the transaction
----------------------------- ------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEASPSALPDEEA
(END) Dow Jones Newswires
August 25, 2023 02:00 ET (06:00 GMT)
Spectral Md (LSE:SMD)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Spectral Md (LSE:SMD)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
